Vactosertib is under clinical development by MedPacto and currently in Phase I for Refractory Acute Myeloid Leukemia.

Vactosertib is under clinical development by MedPacto and currently in Phase I for Relapsed Acute Myeloid Leukemia.

One common form of leukemia is acute myeloid leukemia (AML), characterized by a degradation of early blood cell precursors, ... Patients with acute myeloid leukemia who have lower education levels ...

If you have been diagnosed with acute myeloid leukemia or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. See the latest estimates for new ...

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal ...

Eunice S. Wang, MD, discusses research behind optimal therapy for acute myeloid leukemia secondary to other malignancies, particularly in patients with prior myelodysplastic syndrome. Eunice S. Wang, ...

Fatigue is a key prognostic indicator for adverse outcomes in AML, ALL, and myelodysplastic syndromes. CAR T-cell therapy post-transplant shows a 48% complete remission rate in AML, though not FDA ...

Aug. 21, 2024 — An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that ...